Recent Updates
Recently added Catalysts
AP

Ascendis Pharma A/S

ASNDFDA catalysts, PDUFA dates & pipeline intelligence
$271.19
▼ -0.54 · -0.2%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ASND financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $188.0852W HIGH $282.15
Volume
586.83 K
Value Traded
157.20 M
Short % Float
4.62%
Days to Cover
5.0
+4.59%Week
+17.93%1 Month
+4.46%3 Month
+12.37%6 Month
+78.26%5 Year
+1,049.07%All Time

Cash Data

Unlock ASND cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
17.79 B
EPS (TTM)
9.40
P/E Ratio
28.85
Ent. Value
13.88 B
Total Shares
65.60 M
Float Shares
64.84 M
Insiders
1.16%
Institutions
100.20%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout
TransCon CNP + TransCon hGH
growth disorders
Phase 2PeptidesEndocrine
Unlock every ASND catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ASND Catalyst Timeline

Dated clinical, regulatory and corporate events for Ascendis Pharma A/S

Catalyst Timeline

Dated clinical, regulatory & corporate events for Ascendis Pharma A/S

396Total events
18Upcoming
106Tier-1 (high impact)
2014 to 2030Coverage

Upcoming catalysts 2

T2Timing Guidance
Subscribe to view catalyst details
T2Other Regulator Milestone
Subscribe to view catalyst details
NavepegritideApproved

Event history 50

▲Quarterly UpdateCorporate
Ascendis reports Q3 2026 financial results
▲CHMP Positive OpinionNavepegritideApprovedEx-US Regulatory
CHMP positive opinion recommending EU marketing authorization for once-weekly TransCon CNP in pediatric achondroplasia
achondroplasia in children two years of age and older whose epiphyses are not closedsource ↗
▲EU Orphan DesignationNavepegritideApprovedEx-US Regulatory
COMP positive opinion to maintain orphan designation for TransCon CNP (navepegritide) in pediatric achondroplasia
achondroplasia in childrensource ↗
▲CHMP Positive OpinionNavepegritideApprovedEx-US Regulatory
CHMP positive opinion recommending EU marketing authorization for TransCon CNP in achondroplasia
achondroplasiasource ↗
▲EU Orphan DesignationNavepegritideApprovedEx-US Regulatory
COMP positive opinion recommending maintenance of orphan designation for TransCon CNP
achondroplasiasource ↗
▲Poster PresentationPresentation
Poster at Kidney Week 2026 (ASN) on pooled kidney function data from PaTH Forward and PaTHway
hypoparathyroidismsource ↗
▲Long Term DataClinical Data
Sustained eGFR improvements through up to 5 years (Week 266) of TransCon PTH treatment
hypoparathyroidismsource ↗
▲Pooled AnalysisClinical Data
Pooled analysis of eGFR and 24-hour urine calcium improvements up to 5 years
hypoparathyroidismsource ↗
▲CHMP Positive OpinionNavepegritideApprovedEx-US Regulatory
CHMP adopts positive opinion for TransCon CNP (navepegritide) in pediatric achondroplasia
achondroplasia in childrensource ↗
◆Poster PresentationNavepegritideApprovedPresentation
Poster on improved growth and physical functioning in children with achondroplasia treated with navepegritide in ApproaCH OLE at ASBMR 2026
Achondroplasiasource ↗
Unlock the full ASND catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ASND actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-09TransCon PTH (palopegteriparatide) Phase 2 data presentation Phase 2
Unlock 12 more ASND historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 43%
Mid Cap
(rank 312 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (20-F and 6-K), converted from EUR to USD, to Jun 2026; product lines: last four quarters to Jun 2026 (20-F and 6-K))
ProductRevenuePrior periodChange
YORVIPATH®
SKYTROFA®
Showing 12 of 14 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Lonapegsomatropin BiologicsNCT05690386Turner SyndromePhase 3 ACTIVE NOT_RECRUITING 234Dec 1, 2027
Palopegteriparatide PeptidesMarketedNCT07081997HypoparathyroidismApproved RECRUITING 48Jun 1, 2028
Navepegritide PeptidesMarketedNCT06732895AchondroplasiaApproved ACTIVE NOT_RECRUITING 203Oct 1, 2027
Navepegritide PeptidesNCT07917143HypochondroplasiaPhase 3 NOT YET_RECRUITING 81Oct 1, 2029
Dual therapy with navepegritide and lonapegsomatropin Small MoleculesMarketedNCT07924059AchondroplasiaApproved NOT YET_RECRUITING 144Sep 1, 2029
Lonapegsomatropin Small MoleculesMarketedNCT04615273Growth Hormone DeficiencyApproved COMPLETED 264Dec 1, 2023
Lonapegsomatropin Small MoleculesMarketedNCT05171855Adult Growth Hormone DeficiencyApproved COMPLETED 220Dec 23, 2024
TransCon PTH Small MoleculesMarketedNCT04009291HypoparathyroidismApproved COMPLETED 143Apr 17, 2025
TransCon hGH BiologicsMarketedNCT03344458Growth Hormone DeficiencyApproved COMPLETED 444Feb 21, 2023
TransCon CNP Small MoleculesMarketedNCT05246033AchondroplasiaApproved COMPLETED 221Apr 23, 2024
ACP-001 Small MoleculesMarketedNCT01247675Adult Growth Hormone DeficiencyApproved COMPLETED 37May 1, 2011
ACP-001 Small MoleculesMarketedNCT01947907Growth Hormone Deficiency (GHD)Approved COMPLETED 53Sep 1, 2015
Unlock the ASND pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ASND program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
TransCon PTH
Priority
hypoparathyroidismPhase 2/32026-10-2668.9% of patients achieving clinically meaningful increases in eGFR; mean improvement in eGFR for all patients from baseline to Week 26 was 7.2 mL/min/1.73 m2; mean improvement in eGFR to Week 52 was 9.6 mL/min/1.73 m2; 49.6% of patients achieved an increase in eGFR of >10 mL/min /1.73 m2; mean eGFR slope was 0.28 mL/min/1.73 m2/year; 24-hour urine calcium excretion normalized from mean 396 mg/day at baseline to mean 206 mg/day at Week 26; mean serum calcium increased to 8.9 mg/dL; 98% of patients achieved independence from active vitamin D; 95% of patients achieved independence from therapeutic doses of calciumRead MoreTransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 YearsRead More
Scroll for more · summaries link to the source press release
Unlock every ASND trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ASND insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Bodenhoff MadsOfficer (SVP & PAO)Option 3,000 3,000 held$110.00 09/08/2026
Unlock the full ASND insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
RA CAPITAL MANAGEMENT, L.P. 23.5 % (-1.3 %) 2.34 B 10.28 M
Unlock every fund holding ASND
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ASND
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see ASND ownership
Insider and institutional ownership, quarter by quarter.

ASND Short Interest

Shares sold short, counted twice a month.

4.62%
Short % of Float
of tradable shares sold short
3.0M
Shares Sold Short
-4.3% vs prior count
5.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
600.8K
Avg Daily Volume
the average used for days to cover
Unlock ASND short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock ASND option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ASND option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ASND options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ASND ranks across every disease it competes in

Competitive Position is a premium feature
See how ASND ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ASND News

-ASND
Nov 12, 2026
ASNDGeneral

Ascendis Pharma Reports Third Quarter 2026 Financial Results

Ascendis Pharma reported a strong Q3 2026, with product revenue reaching €366 million, up 89% year-over-year. The company received positive opinions for TransCon CNP from the CHMP and COMP, with a final EC decision expected in Q4 2026. The first EU launch is planned for Germany in Q1 2027, with pivotal data anticipated in Q3 2027.

Read more →
-ASND
Nov 10, 2026
ASNDConferences/Events

Ascendis Pharma to Participate in the Jefferies London Healthcare Conference

Ascendis Pharma A/S will participate in the Jefferies London Healthcare Conference on November 17, 2026. Executives will engage in a fireside chat, and a live webcast will be accessible on the company's website. This event highlights Ascendis' commitment to innovative therapies using their TransCon technology platform.

Read more →
-ASND
Nov 6, 2026
ASNDFDA Updates

Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union

Ascendis Pharma announced a positive recommendation from the EMA's COMP for its once-weekly TransCon CNP for treating achondroplasia in children. This designation could grant 10 years of market exclusivity upon final approval by the European Commission, expected in Q4 2026. The company anticipates launching the treatment in Germany in Q1 2027.

Read more →
-ASND
Nov 5, 2026
ASNDConferences/Events

Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

Ascendis Pharma A/S announced plans to report its third quarter 2026 financial results on November 12, 2026. The company will also provide a business update and host a conference call at 8:00 a.m. ET. The event will be accessible via a live webcast, with a replay available for 30 days.

Read more →
-ASND
Oct 26, 2026
ASNDPhases

TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years

Ascendis Pharma announced positive results from its Phase 2 and Phase 3 trials of TransCon PTH for hypoparathyroidism. The treatment showed significant improvements in kidney function, with 68.9% of patients achieving clinically meaningful increases in eGFR. Additionally, most patients reported independence from conventional therapies and maintained normal serum calcium levels.

Read more →
-ASND
Oct 16, 2026
ASNDFDA Updates

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

Ascendis Pharma announced that the CHMP has issued a positive opinion for marketing authorization of TransCon CNP (navepegritide) for treating achondroplasia in children aged two and older. The final decision by the European Commission is anticipated in Q4 2026, with a potential launch in Germany in Q1 2027. TransCon CNP is designed to provide continuous exposure to active CNP, addressing overactive FGFR3 signaling.

Read more →
-ASND
Oct 6, 2026
ASNDConferences/Events

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

Ascendis Pharma will present updates on its hypoparathyroidism and achondroplasia programs at ASBMR 2026. Key highlights include findings from the Phase 2 and Phase 3 trials demonstrating improvements in bone mass and microarchitecture in patients treated with TransCon PTH. The company emphasizes the potential of its therapies to enhance patient outcomes and quality of life.

Read more →
-ASND
Sep 14, 2026
ASNDGeneral
▼ -9.5%on this news

Ascendis Announces Planned $400 Million Share Repurchase Program

Ascendis Pharma A/S has announced a $400 million share repurchase program authorized by its Board of Directors. The program allows for repurchases through various methods, depending on market conditions. This initiative reflects the company's confidence in its financial standing and aims to enhance shareholder value.

Read more →
-ASND
Sep 14, 2026
ASNDGeneral
▼ -9.5%on this news

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

Ascendis Pharma has announced it will regain exclusive rights to develop TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows the termination of its collaboration with Novo Nordisk. Ascendis plans to initiate multiple new programs, including advancing once-monthly TransCon Semaglutide as a treatment for obesity and type 2 diabetes.

Read more →
-ASND
Sep 9, 2026
ASNDPhases

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

Ascendis Pharma presented positive Week 52 data from the reACHin Trial for TransCon CNP, showing stabilization or improvement in foramen magnum stenosis and enhanced linear growth in infants with achondroplasia. The treatment was well tolerated, with no significant adverse events reported. The results suggest that early intervention with TransCon CNP could effectively address growth limitations and medical complications associated with the condition.

Read more →
-ASND
Sep 8, 2026
ASNDConferences/Events

Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Ascendis Pharma A/S will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Executives will engage in a fireside chat, which will be available via live webcast and for replay on their website. The company emphasizes its focus on innovative therapies using its TransCon technology platform.

Read more →
-ASND
Sep 7, 2026
ASNDConferences/Events

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026

Ascendis Pharma will present new data from its Endocrinology Rare Disease programs at ESPE 2026 in Marseille. Key highlights include the first cohort data from the pivotal reACHin Trial of TransCon CNP in infants with achondroplasia. The company aims to demonstrate the potential benefits of early intervention in this patient population.

Read more →
-ASND
Aug 31, 2026
ASNDGeneral
▲ +6.1%on this news

Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)

Ascendis Pharma has entered a binding term sheet with BioMarin for a global settlement and license agreement concerning YUVIWEL and related products. The agreement resolves all litigation and allows Ascendis to develop and commercialize navepegritide-related products. Ascendis anticipates substantial revenue growth and aims to achieve €5 billion in revenue by 2030.

Read more →
-ASND
Aug 25, 2026
ASNDConferences/Events

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

Ascendis Pharma announced an oral presentation of Week 104 data from its pivotal ApproaCH Trial at ISDS 2026. The trial focuses on TransCon CNP (navepegritide) for treating achondroplasia in children. The data indicates significant benefits, including improvements in height and physical functioning, with a favorable safety profile. The FDA has already approved TransCon CNP under the name YUVIWEL.

Read more →
-ASND
Aug 13, 2026
ASNDGeneral

Ascendis Pharma Reports Second Quarter 2026 Financial Results

Ascendis Pharma reported a significant increase in product revenue for Q2 2026, totaling €315 million, driven by strong sales of YORVIPATH, SKYTROFA, and YUVIWEL. The company highlighted successful trial data presentations and completion of key enrollment milestones. Ascendis also settled its convertible notes and was added to multiple Russell U.S. Indexes, indicating a strong market position.

Read more →
-ASND
Aug 6, 2026
ASNDConferences/Events

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Pharma A/S announced plans to report its second quarter 2026 financial results and provide a business update on August 13, 2026. A conference call will follow the report, allowing investors to engage with the company. The announcement highlights Ascendis' commitment to transparency and innovation in addressing patient needs.

Read more →
-ASND
Aug 6, 2026
ASNDPhases

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Ascendis Pharma announced positive results from the Phase 2 COACH Trial, showing significant growth improvements in children with achondroplasia using TransCon CNP and TransCon hGH combination therapy. The company also reported successful enrollment in the pivotal reACHin Trial for infants and noted a strong uptake of YUVIWEL in the U.S., with over 65% of patients approved for reimbursement.

Read more →
-ASND
Jun 30, 2026
ASNDPhases

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

Ascendis Pharma reported positive results from the ApproaCH Trial, showing that children with achondroplasia treated with TransCon CNP demonstrated sustained improvements in lower extremity alignment over 104 weeks. The trial highlighted significant reductions in tibial-femoral angle, particularly in children with preexisting genu varum. The treatment was well tolerated, with no serious adverse events reported.

Read more →
-ASND
Jun 26, 2026
ASNDGeneral

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

Ascendis Pharma A/S has announced its inclusion in several Russell U.S. Indexes, including the Russell 3000, Russell 1000, Russell 2500, and Russell Midcap. This change is effective as of June 26, 2026, and reflects the company's growing market presence. The Russell Indexes are widely utilized by investment managers, indicating potential for increased investment interest.

Read more →
-ASND
Jun 25, 2026
ASNDConferences/Events

Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

Ascendis Pharma will present new data on treatments for achondroplasia at ICCBH 2026. The presentations include Week 104 data from the pivotal ApproaCH Trial and findings from the COACH Trial. These results highlight the benefits of TransCon CNP and its combination with TransCon hGH, addressing significant unmet needs in affected children.

Read more →

About Ascendis Pharma A/S

1,189 employees ascendispharma.com
HeadquartersHellerup
Founded2006
BIOPHARMAWATCH ELITE
Trade the next ASND catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime